Understanding how S100A7 affects aggressive breast cancer in African American women
Unravel the novel role of S100A7 and its functional partners in Metastatic Triple Negative Breast Cancer Racial Disparity
This study is looking at a protein called S100A7 and how it affects triple-negative breast cancer, especially in African American women who are more likely to face serious challenges from this disease, with the hope of finding new ways to improve treatment for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10946343 on NIH RePORTER |
What this research studies
This research investigates the role of S100A7 in triple-negative breast cancer (TNBC), particularly focusing on its impact on African American women who experience higher mortality rates from this disease. The study explores how S100A7 interacts with immune signaling pathways to create a tumor microenvironment that promotes cancer progression and metastasis. By analyzing patient samples and using pre-clinical models, the researchers aim to uncover mechanisms that contribute to the aggressive nature of TNBC in this population. The ultimate goal is to identify potential therapeutic targets that could improve treatment outcomes for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with triple-negative breast cancer.
Not a fit: Patients with non-triple-negative breast cancer or those outside the African American demographic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms driving aggressive TNBC in African American women.
How similar studies have performed: Previous research has shown promising results in targeting immune pathways in breast cancer, suggesting that this approach may yield significant insights and advancements.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Ganju, Ramesh K. — Ohio State University
- Study coordinator: Ganju, Ramesh K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.